Briuglia Maria-Lucia, Rotella Chiara, McFarlane Amber, Lamprou Dimitrios A
Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), University of Strathclyde, 161 Cathedral Street, Glasgow, G4 0RE, Scotland, UK.
Drug Deliv Transl Res. 2015 Jun;5(3):231-42. doi: 10.1007/s13346-015-0220-8.
Cholesterol plays a strategic role in liposome composition; however, the quantity used to achieve an appropriate formulation has not been yet clarified. Therefore, by screening arrangement of lipids and cholesterol ratio, the main aim of this study is to investigate the most suitable amount of cholesterol in lipids in order to prepare stable and controlled drug release vehicles. For the preparation of liposomes, DMPC, DPPC and DSPC phospholipids were used and combined with different molar ratios of cholesterol (e.g. 100, 80-20, 70-30, 60-40 and 50-50%). Stability studies were conducted by storing the formulations at 37 and 50 °C for 30 days and by analysing them by AFM, DLS and FT-IR. By detecting the two most stable formulations from the stability results, drug encapsulation and in vitro release studies in PBS were performed by encapsulating atenolol and quinine. The release results were validated using a simulation model to ensure the reliability and suitable interpretation of the data. The generated model showed a good correlation between the prediction and the in vitro obtained results. By using 70:30% ratio (known in literature as 2:1), it is possible to reach the most stable formulation to guarantee a controlled and reproducible release for drugs with different physicochemical characteristics and pharmaceutical applications.
胆固醇在脂质体组成中起着关键作用;然而,用于实现合适配方的胆固醇用量尚未明确。因此,通过筛选脂质排列和胆固醇比例,本研究的主要目的是探究脂质中最适宜的胆固醇用量,以制备稳定且可控释药的载体。制备脂质体时,使用了二肉豆蔻酰磷脂酰胆碱(DMPC)、二棕榈酰磷脂酰胆碱(DPPC)和二硬脂酰磷脂酰胆碱(DSPC)磷脂,并与不同摩尔比的胆固醇(如100%、80 - 20%、70 - 30%、60 - 40%和50 - 50%)混合。通过将制剂在37℃和50℃下储存30天,并采用原子力显微镜(AFM)、动态光散射(DLS)和傅里叶变换红外光谱(FT - IR)对其进行分析来开展稳定性研究。从稳定性结果中检测出两种最稳定的制剂后,通过包封阿替洛尔和奎宁进行了药物包封及在磷酸盐缓冲液(PBS)中的体外释放研究。使用模拟模型对释放结果进行验证,以确保数据的可靠性和恰当解读。所生成的模型显示预测结果与体外获得的结果之间具有良好的相关性。通过使用70:30%的比例(文献中称为2:1),有可能获得最稳定的制剂,从而保证对具有不同理化特性和药物应用的药物实现可控且可重复的释放。